Infliximab in the treatment of severe steroid-refractory ulcerative colitis a pilot study

In the psoriasis Study II, which included both the 5 mg/kg and 3 mg/kg doses, antibodies were observed in 36% of patients treated with 5 mg/kg every 8 weeks for 1 year, and in 51% of patients treated with 3 mg/kg every 8 weeks for 1 year. In the psoriasis Study III, which also included both the 5 mg/kg and 3 mg/kg doses, antibodies were observed in 20% of patients treated with 5 mg/kg induction (weeks 0, 2 and 6), and in 27% of patients treated with 3 mg/kg induction. Despite the increase in antibody formation, the infusion reaction rates in Studies I and II in patients treated with 5 mg/kg induction followed by every 8 week maintenance for 1 year and in Study III in patients treated with 5 mg/kg induction (%%) and serious infusion reaction rates (<1%) were similar to those observed in other study populations. The clinical significance of apparent increased immunogenicity on efficacy and infusion reactions in psoriasis patients as compared to patients with other diseases treated with REMICADE over the long term is not known.

Only your doctor can recommend a course of treatment after checking your health condition. REMICADE ® (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those 65 years and older, have had serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE ® .

About the Biologics Price Competition and Innovation Act of 2009
The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) was passed as part of the Affordable Care Act that President Obama signed into law in March 2010. The BPCI Act created an abbreviated licensure pathway for biological products shown to be “biosimilar” to or “interchangeable” with an FDA-licensed biological product, called the “reference product.” This abbreviated licensure pathway under section 351(k) of the Public Health Service Act permits reliance on certain existing scientific knowledge about the safety and effectiveness of the reference product, and enables a biosimilar biological product to be licensed based on less than a full complement of product-specific preclinical and clinical data.

Infliximab in the treatment of severe steroid-refractory ulcerative colitis a pilot study

infliximab in the treatment of severe steroid-refractory ulcerative colitis a pilot study

Media:

infliximab in the treatment of severe steroid-refractory ulcerative colitis a pilot studyinfliximab in the treatment of severe steroid-refractory ulcerative colitis a pilot studyinfliximab in the treatment of severe steroid-refractory ulcerative colitis a pilot studyinfliximab in the treatment of severe steroid-refractory ulcerative colitis a pilot studyinfliximab in the treatment of severe steroid-refractory ulcerative colitis a pilot study

http://buy-steroids.org